Investors were shocked to learn that Biogen now plans to pursue regulatory approval for the experimental Alzheimer’s disease drug they previously pulled the plug on. But Heard on the Street's Charley Grant explains why the optimism may be premature. Photo: Brian Snyder/Reuters
from WSJ.com Video - Most Viewed WSJ Videos https://ift.tt/2WeYFIB
Wednesday, 23 October 2019
Biogen’s Alzheimer’s Revelation Isn’t So Simple
About viral
alistarbot is a blogger resources site is a provider of high quality blogger template with premium looking layout and robust design
WSJ.com Video - Most Viewed WSJ Videos
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment